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Abstract
Background and Aims: Increasing evidence that a number of malignancies are characterised by tumour cell heterogeneity
has recently been published, but there is still a lack of data concerning liver cancers. The aim of this study was to investigate
and characterise tumour-propagating cell (TPC) compartments within human hepatocellular carcinoma (HCC).
Methods: After long-term culture, we identified three morphologically different tumour cell populations in a single HCC
specimen, and extensively characterised them by means of flow cytometry, fluorescence microscopy, karyotyping and
microarray analyses, single cell cloning, and xenotransplantation in NOD/SCID/IL2Rc2/2 mice.
Results: The primary cell populations (hcc-1, -2 and -3) and two clones generated by means of limiting dilutions from hcc-1
(clone-1/7 and -1/8) differently expressed a number of tumour-associated stem cell markers, including EpCAM, CD49f, CD44,
CD133, CD56, Thy-1, ALDH and CK19, and also showed different doubling times, drug resistance and tumorigenic potential.
Moreover, we found that ALDH expression, in combination with CD44 or Thy-1 negativity or CD56 positivity identified
subpopulations with a higher clonogenic potential within hcc-1, hcc-2 and hcc-3 primary cell populations, respectively.
Karyotyping revealed the clonal evolution of the cell populations and clones within the primary tumour. Importantly, the
primary tumour cell population with the greatest tumorigenic potential and drug resistance showed more chromosomal
alterations than the others and contained clones with epithelial and mesenchymal features.
Conclusions: Individual HCCs can harbor different self-renewing tumorigenic cell types expressing a variety of
morphological and phenotypical markers, karyotypic evolution and different gene expression profiles. This suggests that
the models of hepatic carcinogenesis should take into account TPC heterogeneity due to intratumour clonal evolution.
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Introduction
Like many other solid tumours, hepatocellular carcinomas
(HCCs) are characterised by a high degree of heterogeneity that is
traditionally explained on the basis of one of two models of
carcinogenesis: the stochastic model and the hierarchy model. The
stochastic model predicts that a malignancy consists of a
homogeneous population of cells that generate their heterogeneity
and tumour-initiating potential in response to particular combi-
nations of endogenous factors (gene dose effects, and transcrip-
tional and translational control mechanisms) and exogenous
factors (cytokine concentrations, cell-to-cell interactions and,
particularly, a niche environment). The hierarchy model predicts
that the organisation of a malignancy is similar to that of normal
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tissue hierarchy, with tumour-initiating cells producing identical
daughter stem cells with a capacity for self-renewal and committed
progenitor daughter cells with a limited (but potentially still
significant) capacity to divide.
Over the last ten years, increasing evidence has been published
indicating that tumour maintenance and growth are sustained by a
minority population of tumour-propagating cells (TPCs) or cancer
stem cells (CSCs) [1–5]. This is also true of liver cancer [6–8], and
may have important diagnostic and therapeutic implications [9]. It
was initially argued that the CSC model is essentially synonymous
with the hierarchy model of carcinogenesis [10], but it has recently
been suggested that it is compatible with both models [11] because
‘‘stemness’’ exists as a functional phenotype in the stochastic model
and could be shown by any member of the malignant population
in the presence of the appropriate endogenous and exogenous
factors.
Efforts have recently been made to accommodate a further
biological phenomenon in the models of carcinogenesis, because
there is now convincing evidence that cancer cells are subject to a
process known as clonal evolution: i.e. the continuous develop-
ment of new clones characterised by new genetic (and possibly
epigenetic) changes. Cancer cells constantly need to adapt to
environmental pressures and these adaptations may affect their
proliferation, metastatic potential or drug resistance, a process that
can be reconciled with both the CSC and stochastic models of
heterogeneity [11]. However, the clonal evolution model has not
yet been fully applied to studies of liver CSCs, because most
experiments have used clonally derived cancer cell lines that have
been cultured for decades and therefore consist of relatively
homogenous cell populations. In this regard, it is currently agreed
that studies of TPCs should be extended to cells directly isolated
from primary cancers [12].
In our early experiments, we isolated and expanded TPCs from
primary human HCC specimens by adapting methods that have
been successfully used to isolate normal liver stem cells [13]. The
first samples came from small HCCs obtained after surgical
resection, but we could not prolong epithelial cell cultures beyond
the third or fourth passage. Based on our hypothesis that this was
due to the small size of the specimens in relation to the total
tumoral mass and the rarity of TPCs, we subsequently concen-
trated on larger nodules (.5 cm in diameter) and found that
morphologically and phenotypically different cell populations
could be cultured from the same tumour specimen. More
specifically, three distinct and stable primary tumour propagating
cell lineages (hcc-1, hcc-2 and hcc-3) obtained from a 74-year-old
male patient with advanced HCC were expanded and extensively
characterised by means of flow cytometry, fluorescence microsco-
py, karyotyping and microarray analyses, single cell cloning, and
xenotransplantation in NOD/SCID/IL2Rc2/2 (NSG) mice. The
results indicate that the clonal evolution of TPCs is a driver of
intra-HCC heterogeneity.
Materials and Methods
Ethics Statement
The study patients gave their written informed consent before
undergoing HCC resection, and the study was approved by the
Institutional Review Board of the Fondazione IRCCS Ca’ Granda
Ospedale Maggiore Policlinico. Experiments involving animals
were done in accordance with the Italian Laws (D.L.vo 116/92
and following additions, which enforces EU 86/609 Directive).
According to the regulatory requirements, the European
Institute of Oncology animal facility is fully authorized by the
Italian Ministry of Health (DM Nu 65/2007-A) and the project has
been notified to the Ministry of Health with ID number 11/09.
Liver cell isolation and long-term cell cultures
After appropriate samples had been taken for histological
purposes, a liver tumour tissue specimen was collected and
dissociated as previously described [13].
The cell suspensions obtained from the tumoral tissue were
cultured onto collagen-coated Petri dishes at a density of 56105
cells/cm2 in IMDM, supplemented with 20% FBS, 1% non-
essential amino acids, 1% glutamine, and 1% penicillin/strepto-
mycin (Invitrogen, Carlsbad, CA, USA). The medium was changed
24 hours after seeding in order to remove dead cells and debris, and
was then replaced twice a week; the cells were maintained at 37uC
in a humidified 5% CO2 incubator. After the appearance of
colonies of 50–100 cells (usually after 14–20 days), the cells were
replated in plastic flasks. Colonies with different cell morphologies
were picked up separately and replated in different flasks. Confluent
cells were detached using trypsin/EDTA (Invitrogen), counted and
replated 1:3 at every split in order to determine their growth
kinetics.
Three morphologically different cell colonies (hcc-1, hcc-2 and
hcc-3) were raised in culture from a single specimen of about 15
grams taken from a male patient with trabecular HCC who was
HBsAg and anti-HCV negative and had no clinical or histological
evidence of liver cirrhosis.
In vitro clonogenicity
In order to determine whether heterogeneity was an intrinsic
property of the three cell populations, each one was plated as a
single cell by means of limiting dilution in 96-well plates. Clones
with .50 cells were scored after three weeks, picked up and plated
alone in flasks; cloning efficiency was defined as the percentage of
cells developing a clone. The clones were characterised by flow
cytometry at the first and fifth culture passages, after which only
those whose morphological and/or phenotypical profile were
different from the original mother population were further
characterised. Moreover, once we had evaluated the tumorigenic-
ity in vivo of the three HCC cell lineages (see paragraph below)
and since previous reports support the evidence that in vitro
clonogenicity is related to in vivo tumorigenicity [7,14–15], we
performed single cell sorting on 96 well plates using FACSAria II
equipped with FACSDiva software (BD) in order to evaluate the
presence of a more clonogenic, and therefore theoretically more
tumorigenic, subpopulation within the cell lines. In particular, for
all the three HCC cell lines we sorted EpCAM positive and
negative cells; moreover, we also sorted tumour cell lines choosing
another typical specific marker for each of the three cell lines, i.e.
CD44 for hcc-1, Thy-1 for hcc-2 and CD56 for hcc-3. In each
experiment we chose to sort only the brightest and the most
negative cells for each marker; these populations accounted for
about 20% of each compartment. Cloning efficiency was
evaluated as described above.
Flow cytometry characterisation
The cells were characterised at passages 1–3, 9–15, and .30 as
previously described [13], using the following monoclonal
antibodies (moabs): anti-epithelial cell adhesion molecule (Ep-
CAM), anti-Thy-1, anti-ATP binding cassette-G2 (ABCG2), anti-
CD44, anti-CD49f , anti-CD56, anti-CD13, anti-CD166, anti-
CD146, anti-CXCR4, anti-CD105, anti-platelet derived growth
factor receptor-alpha (PDGFr-a) (Becton Dickinson Biosciences,
BD, Franklin Lakes, NJ, USA), anti-CD133-1 (Miltenyi Biotec,
Bergisch Gladbach, Germany), conjugated with fluorescein
Heterogeneity of Tumorigenic Hepatic Cells
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isothiocyanate (FITC) or phycoerythrin (PE) or PE-cyanin 7 (PE-
Cy7) or allophycocyanin (APC) or APC-cyanin 7 (APC-Cy7). The
fluorescence threshold between negative and positive cells was set
on the basis of the reactivity of appropriate non-specific
fluorochrome-conjugated isotypical controls.
Aldehyde dehydrogenase (ALDH) positivity was assessed, both
alone or in combination with membrane-markers staining, on cell
lineages using the Aldefluor kit (Stemcell Technologies, Vancou-
ver, BC, Canada) in accordance with the manufacturer’s
instructions. At least 106 cells were analysed using a FACSCanto
II equipped with FACSDiva software (BD).
Cell fluorescence microscopy
The HCC cell populations and clones were stained at the 15th
and fifth split respectively as previously described [13], using anti-
cytokeratin (CK)18 (Sigma-Aldrich), anti-CK19 (Novocastra, New-
castle, UK), anti-albumin, anti-S100A4 (Dako, Glostrup, Denmark)
and anti-ZO-1 antibodies (BD), and finally FITC or Texas Red-
conjugated secondary antibodies (BD) specific to the appropriate
species. After immunological staining, the nuclei were stained with
4,6-diamidino-2-phenylindole (DAPI, Sigma-Aldrich), and the
images were taken using a Leica Microsystems DM IRE 2
microscope and analysed by means of FW4000I software (Leica
Microsystems, Wetzlar, Germany).
Immunohistochemistry of liver tissue
Formalin-fixed serially cut sections of primary tumour tissue
were stained with hematoxylin and eosin (H&E) and evaluated for
the expression of EpCAM (Santa Cruz, Santa Cruz, CA, USA),
S100A4, CD56 and CK19 (all from Dako). The tissue staining and
image analysis procedures have been described elsewhere [16].
Cytogenetic studies
The tumour cells collected by means of trypsinisation at
passages 3 and .30 were cytogenetically analysed. The cells were
cultured (4 to 6 independent cultures were plated for each cell
lineage and clone) for about a week, and then treated for three
hours with colcemid solution. Chromosome preparations were set
up using conventional techniques [17]. The metaphases were
selected and captured by an ECLIPSE 400 fluorescent microscope
(Nikon, Shinjuku, Japan), and the images were analyzed using
Cytovision System version 2.03 for Windows (Genetix Ltd, New
Figure 1. Different cell proliferation and morphology of the cell populations and clones generated from a single HCC specimen.
A) Growth kinetic curves of the cell populations and clones. Hcc-1, hcc-2 and hcc-3 had doubling times of three, seven and six days respectively (left
panel); hcc-1, clone-1/7 and clone-1/8 had doubling times of three, 4.7 and 3.6 days respectively (right panel). B) Representative phase-contrast
images showing the morphology of the cell populations and clones; original magnification 206.
doi:10.1371/journal.pone.0021369.g001
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Milton, UK). Fluorescent in situ hybridization (FISH) was
performed using conventional protocols [17] and a panel of
probes specific for each chromosome (Multiprobe System-
OctoChrome, Cytocell, Cambridge, UK).
Gene expression analyses
Microarray expression was profiled by the Centre of Molecular
Biomedicine Core Facilities (Trieste, Italy). The expression of
more than 48,000 mRNA transcripts (representing 38,500 genes
involved in cell cycle regulation, apoptosis, matrix adhesion and
cell motility) was assessed by the HumanWG-6 v3 Expression
BeadChip (Illumina, San Diego, CA, USA) in accordance with the
manufacturer’s instructions [18] (see Text S1). The data discussed
in this article have been deposited in NCBI’s Gene expression
Omnibus (GEO) and are accessible through the accession number
GSE24482 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc
=GSE24482).
The abundance of selected transcripts previously identified by
means of microarray expression profiling was re-evaluated using
quantitative PCR (qPCR) [19] (see Text S1 and Table S1).
Drug resistance assay
The cell populations and their clones were further characterised
by analysing their resistance to the chemotherapeutic agent
Sunitinib (formerly SU11248, Pfizer, New York, NY, USA), a
multitargeted tyrosine kinase inhibitor with anti-angiogenic and
anti-tumoral activities that has recently been evaluated in clinical
trials as a treatment for HCC [20].
The cells were treated with 3, 6, 10, 13, 15 and 25 mM of
Sunitinib dissolved in DMSO, and an MTT (3-(4,5 dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide, Sigma-Aldrich) assay was
used to determine the proportion of live cells 24 and 48 hours after
treatment. IC50 values were calculated by means of non-linear
regression analysis using GraphPad Prism version 5.0 software
(GraphPad Software, San Diego, CA, USA), and the differences in
the IC50 values were statistically analysed using two-way ANOVA
on the basis of the results of at least three independent experiments
with four replicates of each cell type per experiment. P values,.05
were considered statistically significant [21].
In vivo tumorigenic potential
In order to verify whether the three cell populations and two
clones contained TPCs, we performed serial xenotransplantation
assays using 6–8 week old male NSG mice (Jackson Laboratory,
Bar Harbor, ME, USA) kept under specific pathogen-free
conditions [22]. In detail, 16106 hcc-1, -2 and -3 cells and
16105 hcc-1, clone-1/7 and -1/8 cells were directly injected into
the liver parenchyma of the anesthetised mice after an abdominal
incision. Since we previously observed a good correlation
between human alphafeto-protein (AFP) plasma levels and tumor
size measured by imaging [23], tail blood samples were collected
and plasma AFP was evaluated using ARCHITECT 2000
(Abbott, Abbott Park, IL, USA) at various time points in order
to estimate the tumour growth. Upon sacrifice, cardiac blood was
collected, and the tumours and metastases were resected for
further analysis.
Results
Long-term cultures
Although they were maintained in long-term culture under the
same conditions, the three primary cell lineages originating from a
single HCC specimen had different growth kinetics and morpho-
logical patterns (Figs. 1A, 1B). In order to confirm that no cross-
contamination with other samples had occurred, the three cell
populations and frozen cells collected immediately after tumour
dissociation underwent DNA Short Tandem Repeat (STR)
analysis (Figure S1).
In vitro clonogenicity
All of the cell populations were capable of generating clones by
limiting dilution with a clonal efficiency of 14% for hcc-1, 12%
for hcc-2, and 6% for hcc-3. Interestingly, all of the hcc-2 and
hcc-3 clones were morphologically and phenotypically identical
to their mother population, whereas hcc-1 generated at least two
clones (clone-1/7 and clone-1/8) with different growth kinetics
and morphologies from those of the mother cell population
(Figs. 1A, 1B).
Fluorescence activated single cell sorting evidenced a statistically
higher clonogenic potential of EpCAM positive tumour cells only
Figure 2. FACS cloning efficiency. Diagrams showing the different
clonogenic potential of the 3 primary HCC cell lines sorted for specific
membrane markers. Columns (mean and standard deviation of 3
independent experiments) represent the percentage of cells which
gave rise to a colony. P,.05 was considered statistically significant
(Chi square test). The lower part of the figure reports the expression of
the sorting marker on each generated colony. All hcc-1, hcc-2 and hcc-3
colonies were positive for EpCAM regardless of whether they were
generated by EpCAM positive or negative sorted cells. The colonies
generated by sorting of the other specific markers, i.e. CD44, Thy-1 and
CD56, did not show any modification of the expression of these
markers.
doi:10.1371/journal.pone.0021369.g002
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in hcc-1 cell line (p = .03, Chi square test). With regard to the other
specific markers, hcc-1 CD44 negative cells, hcc-2 Thy-1 negative
cells and hcc-3 CD56 positive cells were significantly more
clonogenic than their counterparts (p = .0006, p,.0001 and
p = .0001, respectively, Fig. 2). Once wells of the 96 well plates
reached confluence, cells were evaluated for their marker
expression. All hcc-1, hcc-2 and hcc-3 colonies were positive for
EpCAM regardless of whether they were generated by EpCAM
positive or negative sorted cells. On the contrary, colonies
generated by CD44, Thy-1 and CD56 positive or negative cells
did not shown any changes in the expression of these markers
(see figure 2).
Flow cytometry and fluorescence microscopy
characterisation
Between the first and the tenth culture passages, the antigen
expression pattern within each cell culture progressively stabilised.
Figure 3 shows the different antigen expression in the cell
populations and clones after the 30th culture passage. The
phenotypical profiles of hcc-1, -2 and -3 were significantly
Figure 3. Flow cytometry characterisation of the HCC cell populations and clones in terms of the expression of the principal stem
cell, epithelial and mesenchymal markers. A) Marker expression in the cell populations and clones, expressed as percentages of positive cells.
B) ALDH expression in the cell populations and clones. C) Co-expression of the principal stem cell markers on ALDH positive (green dots) and
negative (red dots) cells; hcc-1 left panels, hcc-2 middle panels and hcc-3 right panels, respectively.
doi:10.1371/journal.pone.0021369.g003
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Figure 4. Immunofluorescence of cell culture. A) Double and single immunofluorescence staining of hcc-1, hcc-2, hcc-3, clone-1/7 and clone-1/
8 using anti-CK18, -albumin, -CK19,-S100A4 and -ZO-1 antibodies. All nuclei were stained with DAPI (blue); original magnification 406. B) Percentage
of antigen expression in the three cell populations and clones.
doi:10.1371/journal.pone.0021369.g004
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heterogeneous in terms of EpCAM, CD49f, Thy-1, CD56, CD44,
CD146, ABCG2 and PDGFr-a expression (Fig. 3A); furthermore,
the two clones differed from the mother hcc-1 cell line in terms of
the expression of EpCAM, CD49f, CD133 and CD44 (Fig. 3A).
ALDH activity also varied, being most highly expressed in hcc-3
followed by hcc-1; its expression was also higher in clone-1/7 than
in clone-1/8 (Fig. 3B). ALDH was mainly expressed by CD44
negative cells in hcc-1, hcc-2 and hcc-3 cell lines; moreover,
ALDH positivity was associated to Thy-1 negativity and ABCG2
positivity in hcc-2 and CD56 positivity in hcc-3 cells (Fig. 3C).
Immunofluorescence microscopy showed that CK18 and
albumin were expressed in all of the cell populations and clones,
although the percentages of positive cells and the strength of the
reactivity varied (Fig. 4A), whereas the expression of CK19 and
ZO-1 was restricted to hcc-1, hcc-3 and clone-1/7. There was
intense S100A4 staining in hcc-2 and clone-1/8, but hcc-3 did not
express the protein (Fig. 4B).
Tissue immunohistochemistry
Morphological cell evaluations of different tissue sections
revealed the presence of some micro nodules with small round
cells with little cytoplasm; the external tumoral tissue forming most
of the tumour bulk had larger cells resembling typical mature
epithelial cells (Figs. 5A, 5B). This heterogeneity was confirmed by
Figure 5. Immunohistochemistry of primary HCC tissue. The staining was chosen on the basis of the characteristic markers of the three cell
populations detected in culture: CD56, CK19, S100A4 and EpCAM. A and B) H&E staining showing cell morphology heterogeneity in different tumour
areas. C) Left panels: serial tissue sections showing areas with the phenotype resembling hcc-1 (CD562/CK19+/S100A42/EpCAM+) and hcc-2
(CD562/CK192/S100A4+/EpCAM+/2); right panels: higher magnifications of the areas indicated by the black rectangles. D) Left panels: serial tissue
sections showing an area resembling the phenotype of hcc-3 (CD56+/CK19+/S100A42/EpCAM+); right panels: higher magnifications of the areas
indicated by the black rectangles.
doi:10.1371/journal.pone.0021369.g005
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the immunological staining of serial tumor sections. In particular,
as in the case of the immunofluorescence staining, there was a
micro nodule that was positive for S100A4 but negative for CD56
and CK19, and another that was positive for CD56 and CK19 but
negative for S100A4 (Figs. 5C, 5D). Several examined sections
showed widespread staining indicating EpCAM tissue expression,
with the more or less intensely stained areas approximately
corresponding to the S100A4 negative or positive nodules (see in
particular fig. 5D and Figure S2).
Genomic aberrations
Karyotyping and FISH analyses showed that the three cell
populations had complex hypotetraploid karyotypes (Figure S3).
As expected, the populations and clones shared many common
clonal alterations as they were cultured from the same tumour
sample, but they also had some distinctive features (Fig. 6A). All
of them shared translocation t(1:8) and the gain of 1q, which may
be early genomic alterations in HCC development [24]: the first
may confer a growth advantage [25] and the second contains
several candidate oncogenes [24]. Loss of 1p and 8p was only
observed in the hcc-2 and hcc-1 cells and the clones, thus
suggesting a more advanced occurrence [26]; the loss of 13q
was only observed in hcc-1 and its clones, which suggests a late
onset [27].
The alterations accumulating from hcc-3 to hcc-1 could be
fitted in a dendrogram showing the hypothetical clonal evolution
of the cell populations and the clones (Fig. 6B). The presence of the
same chromosomal abnormalities in more than two independent
cultures of each cell lineage and clone, together with the presence
of the same chromosomal alterations at both early (3rd split) and
late culture passages (.30th split), indicated that they probably had
not arisen in vitro.
Microarray and qPCR
Unsupervised analyses of the 1196 most variable genes across the
dataset generated a dendrogram showing, as expected, a low
dissimilarity among hcc-1 and its clones, while hcc-2 showed higher
differences and hcc-3 had the most different expression profile (Fig. 7A).
Figure 6. Clonal genomic alterations in the cell populations and clones. A) Gains, losses and rearrangements in the three populations
observed at both the 3rd and.30th culture passages, thus indicating that the main clonal chromosomal abnormalities are likely to have been present
in the primary tumour. Clone-1/7 and 1/8 were examined at the 30th culture passage. B) Dendrogram reproducing the development of genomic
alterations and the possible clonal evolution of the populations and clones. Hcc-2 probably lost the der(17)t(12;17) during its evolution process. For
each cell lineage and clone the stem cell marker status is reported. The signs plus (+) and minus (2) mean that more or less than 30% of the cells
were positive or negative for that marker, respectively.
doi:10.1371/journal.pone.0021369.g006
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Figure 7. Microarray results of whole genome analysis. A) Heat map showing the clusterization of lineages and clones based on the
expression profile of the 1196 most variable genes across the data set. B) Venn diagram indicating the distribution of the 3112 genes differently
expressed in the supervised analyses. C) Heat map showing differently expressed levels of liver progenitor, epithelial and mesenchymal genes among
HCC lineages and clones. Lineages and clones are arranged to evidence the transition from an epithelial expression pattern to a mesenchymal one.
doi:10.1371/journal.pone.0021369.g007
Heterogeneity of Tumorigenic Hepatic Cells
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Supervised analyses of hcc lineages and clones performed on the
16964 normalized expression values permitted to generate a Venn
diagram showing the distribution of the 3112 genes that resulted
differently expressed among the different comparisons (Fig. 7B).
We evidenced that the 187 genes that resulted differentially
espressed in all comparisons are enriched in genes involved in cell
lipid catabolism, peptidase inhibitor activity, glycoprotein biosyn-
thesis, regulation of transcription, and extracellular and membrane
components.
The heatmap of ‘‘epithelial-to-mesenchymal transition’’ [28]
(EMT) genes revealed that hcc-3, followed by hcc-1, expressed high
levels of progenitor and epithelial genes, whereas hcc-2 expressed
higher levels of the mesenchymal ones. Similarly, clone-1/7
expressed higher levels of epithelial progenitor genes and lower
levels of the EMT ones, while clone-1/8 had a more mesenchymal
pattern of gene expression than hcc-1 in toto (Fig. 7C).
Quantitative PCR of seven genes characteristic of the cell
populations and clones showed the same expression pattern as that
revealed by the microarrays (Figure S4).
Resistance to sunitinib
Hcc-1 showed greater resistance to sunitinib than hcc-2 or hcc-3
after both 24 and 48 hours of treatment at concentrations
of .3 mM (P,.01, 2-way ANOVA), whereas there were no
differences between hcc-2 and hcc-3 at any concentration or time
point. Interestingly, clone-1/7 was more resistant than clone-1/8
or hcc-1 in toto at each concentration after both 24 and 48 hours
(P,.001); on the contrary, clone-1/8 was less resistant than hcc-1
in toto after 24 hour treatment with 6 mM (P,.05) but remained
different after 48 hours of treatment only at sunitinib doses of 3–
10 mM (P,.05, Fig. 8).
Tumorigenic potential
In order to test the capacity of the cell populations to initiate in
vivo tumour formation, we carried out intra-hepatic transplanta-
tions into NSG mice. As the primary HCC secreted AFP, we
monitored blood AFP levels during the post-transplant period and,
when the mice showed high AFP levels and/or signs of illness, they
were immediately sacrificed and examined for tumour formation.
All of the mice injected with hcc-1, -2 and -3 (n = 21; seven per
cell population) developed hepatic tumours (Fig. 9A) and/or
abdominal tumours, but the time courses were different. The mice
inoculated with hcc-1 had detectable AFP levels seven days after
the injection, whereas those injected with hcc-2 or hcc-3 did not
have detectable AFP levels until 56 and 22 days after the injection
respectively (Fig. 9B).
The mice transplanted with hcc-1 had a shorter median survival
(51 days) than those receiving hcc-2 or hcc-3 (111 and 67.5 days
respectively; P = .012 by Kaplan-Meier survival analysis) (Fig. 9C).
Interestingly, hcc-1 was more tumorigenic than its clones, as
shown by the size of the generated tumour and the different AFP
levels measured 20 days after the injection (Figs. 9A, 9B).
Moreover, clone-1/8 generated a detectable liver tumour in only
one of the three transplanted mice, and its AFP levels measured 35
days after the injection were significantly lower than those of the
other clone or hcc-1 (060, 1856183 and 23906694 ng/ml
respectively; P = .0007, one way ANOVA) (Fig. 9B).
The dissociated xenografted tumours arising from the three cell
populations generated cell cultures that fully recapitulated the
phenotypical profile of the injected cells, and also generated
secondary tumours if retransplanted into NSG mice (data not
shown).
Discussion
We isolated and expanded ex vivo three different cell populations
from a single mass of advanced HCC after enzymatic dissociation
of a highly representative portion of the total tumour mass
(.80%). Single cell cloning experiments showed that hcc-1 was
not a homogeneous lineage, but contained at least two distinct
subpopulations (clone-1/7 and -1/8). However, all of the lineages
were capable of forming clones that gave rise to progenies with the
same immunophenotypical characteristics as those found in the
original cultures.
Under identical culture conditions, the three populations and
two clones had distinct morphological, phenotypical and gene
expression profiles. Their growth patterns, the clonogenic assays
and the xenotransplantation experiments clearly indicated that
they all had tumour propagating capability, although the efficacy
Figure 8. Drug resistance of the cell populations and clones. The MTT evaluation showed that the cell populations and clones had different
chemoresistance to sunitinib after 24 (left) and 48 (right) hours of treatment. Mean 6 standard deviation of three independent experiments.
doi:10.1371/journal.pone.0021369.g008
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varied. Moreover, the xenografted tumour cells were capable of
regenerating the originally inoculated populations, and maintained
their tumorigenic potential and distinct features in secondary
transplantations.
Karyotyping and FISH analyses showed that hcc-1, -2 and -3 and
clone-1/8 were genetically distinct and, on the basis of their patterns
of clonal abnormalities, we tracked their hypothetical evolution
process. The oldest was hcc-3, followed by hcc-1 and hcc-2.
Furthermore, our data agree with the current models of the step-
wise progression of hepatocarcinogenesis [26–27], according to
which the gain of 1q (present in all three cell populations) is a marker
of early HCC, whereas losses of 8p (as in hcc2 and hcc1) and 13q (as
in hcc-1 and its clones) are associated with clinical progression.
Nodules whose phenotypical characteristics were concordant
with the three cell populations were clearly identifiable in the
primary tumour tissue. Hcc-3 may have originated from a CD56+/
CK19+/EpCAM+ microscopic nodule, and hcc-2 from a S100A4+/
CK192/CD562 microscopic nodule; the majority of the tumour
mass (which was negative for CD56 and S100A4 but expressed
EpCAM and CK19) generated hcc-1, the most aggressive of the
three cell populations. Other independent elements strongly
indicate that the cell populations were not generated in culture:
the three cell lineages remained functionally and phenotypically
stable for more than one year after isolation; the genetic diversity of
the populations was documented in the very early culture passages,
with no new clonal chromosome abnormality occurring between
Figure 9. Tumorigenicity in vivo. A) Representative liver tumours generated in NSG mice injected with the three cell populations and clones.
B) Human AFP detection in blood from mice inoculated with 16106 hcc-1, -2 and -3 cells (left; n = 21, 7 per group) and with 16105 hcc-1, clone-1/7
and clone-1/8 (right; n = 9, 3 per group). C) Different rate of mouse survival after hcc-1, -2, -3 inoculations (left; P = .012) and hcc-1, clone-1/7 and
clone-1/8 inoculations (right; P = .08).
doi:10.1371/journal.pone.0021369.g009
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the third and the last passage analyzed. Although we cannot
completely exclude the occurrence of genetic changes between
passage 1 and 3, this possibility seems unlikely based on previous
reports [29–31]. Finally, as already mentioned, the hcc-1 popula-
tion, which was the most representative population in the native
tumour mass, was also the most phylogenetically rearranged.
Our data suggest that TPCs in the liver can be organised with a
branching clonal architecture, and that a simple CSC model is not
applicable to hepatocarcinogenesis. Our findings are novel in the
field of liver carcinogenesis, but fit very well with previous
observations in both hematological and solid tumours. Park et al.
[32] have very recently documented the genetic heterogeneity of
stem cell-like breast cancer cells within the same tumour.
Preliminary experiments by Greaves’ group [33] have demon-
strated that the serial transplantation of genetically distinct clones
of acute lymphoblastic leukemia cells from the same patient leads
to the regeneration of leukemia in NSG mice at a level of genetic
complexity that reflects the original diagnostic sample, which
indicates that TPCs are genetically diverse. Finally, in an
experimental setting very similar to our own, Piccirillo et al. [34]
isolated two different populations of cancer cells from a single
specimen of glioblastoma, which grew independently ex vivo and
had different tumorigenic potential and genetic anomalies.
Morphological heterogeneity has long been recognised in HCC,
and it has been recently shown that clinical HCC progression is
related to the sequential accumulation of genomic aberrations
[26]. In addition, clinical studies have shown that late HCC
recurrences after surgery are frequently caused by clones that are
distinct from those of the primary tumour [35]. It is possible that
the heterogeneity of our patient’s tumour mass was even greater
than that described here because, as recently pointed out [34],
other cell populations that are not capable of growing in culture
may have been eliminated upon cell isolation.
However, our data are not irreconcilable with a more complex
CSC hypothesis. As recently underlined [36], a comprehensive
model combining the stem cell and clonal evolution theories
simply moves the dynamics of intra-tumour evolution from the
cancer cell population as a whole to the stem cell compartment.
Our different populations contained elements with stem cell
properties [9], including self renewal, differentiation, and tumour
initiation capacity. They also contained (with different patterns
and frequencies) the markers that have been previously identified
in CSCs of epithelial tumours, including EpCAM, CD49f, CD133,
CK19, CD44, ABCG2 and ALDH.
The evidence that only a minority of cells within the 3 cell
lineages had cloning capacity (between 6 and 14%) suggested that,
as already reported, tumour propagating ability may be restricted
only to certain elements. Single cell sorting experiments showed
different clonogenicity according to the expression of CD44, Thy-1
and CD56 antigens with a clear relation between the expression of
these markers and ALDH activity which deserves further studies.
The different cell populations had different chemoresistance
profiles. Resistance to sunitinib was directly related to tumorige-
nicity, and inversely related to the degree of membrane expression
of PDGFr-a, one of the drug’s main targets. Clonal organisation of a
tumour may greatly affect treatment outcome because neoplastic
evolution tends to select TPCs with treatment resistant features [37].
We also observed that hcc-3 and clone-1/7 were oriented towards a
liver progenitor phenotype (EpCAM, ZO-1, CK19, ALDH, CD56
positivity); hcc-2 and clone-1/8 had the typical features of EMT
(Thy-1, CD105, S100A4 positivity); and hcc-1, which had a mature
epithelial morphology, had an intermediate phenotype that
included both epithelial and mesenchymal markers. These data
were also confirmed by differential gene expression analysis.
Although it is known that EMT in liver cancer is facilitated by
genomic cell alterations [38], we cannot exclude the possibility
that the EMT characteristics were also partially acquired ex vivo as
an adaptation to culture conditions. However, the phenotypical
features of the cell populations remained stable even after
xenotransplantation, which makes this less likely.
We can only speculate on the different mechanisms that may
maintain and promote this intra-tumour clonal heterogeneity
because experimental evidence in humans is very limited [32,37].
It is currently agreed that spatial restrictions in solid tumours lead
to the generation of separate niches that favour the growth of
cells with different characteristics. In addition, various types of
cooperation among tumour cell populations have been proposed,
including parasitism and commensalism [37]. Interestingly, the
hcc-1 cells (which had both epithelial and mesenchymal features)
were characterized by greater tumorigenic potential and a higher
growth rate than clone-1/7 (epithelial) or clone-1/8 (mesenchy-
mal) alone. An educated hypothesis that deserves exploration in
future studies is that EMT, which plays a crucial role in
tumorigenesis and cancer progression [38–42], leads to cells that
are not necessarily more tumorigenic per se, but can produce a
suitable microenvironment for epithelial stem cell growth, and
eventually co-migrate to a new organ and enhance the formation
of metastases.
Conclusion
In conclusion, we provide the first evidence that the same HCC
mass can contain genetically distinct cell populations with
independent tumour propagating capability, but significantly
different phenotypical and functional characteristics. Our findings
offer new perspectives for the design of a comprehensive model of
hepatocarcinogenesis that takes into account the clonal evolution
of TPCs, and the definition of novel therapeutic strategies for
advanced HCC.
Supporting Information
Figure S1 STR analysis. The primary dissociated tumour
sample and hcc-1, hcc-2 and hcc-3 showed the same STR profile
confirming that the cell populations originated from the same
patient.
(TIF)
Figure S2 Representative tissue sections showing the
EpCAM and S100A4 staining pattern. Broken lines evidences
areas positive for EpCAM and less intensely positive for S100A4;
continuous lines evidences areas positive for S100A4 and negative
for EpCAM. Original magnification 56.
(TIF)
Figure S3 Representative karyotypes of the three cell
populations and clones. Some of the clonal alterations are
indicated by arrows; the red arrows indicate the clonal alterations
specific to clone-1/8.
(TIF)
Figure S4 Gene expression validation. A) Microarray and
B) qPCR expression values of selected genes in the cell lines and
clones. The bars represent the mean relative expression values of
three independent RNA isolations analysed in triplicate. For the
qPCR analyses, all of the genes were normalised to CYC as the
reference housekeeping gene. All of the data are presented as log2
transformations of gene-normalised signals. The qPCR results
showed the same consistent modulation as the microarray analysis.
(TIF)
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Table S1 Primer and probe sequences used in the qPCR
experiments.
(TIF)
Text S1 Supplementary Materials and Methods.
(DOC)
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